Non melanotic malignant neoplasm of the skin - Cutaneous contact with high concentrations of polycyclic aromatic hydrocarbons Factor
RMA definition
The RMA has defined "agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified" to mean:
- concentrated coal tar distillates;
- creosote;
- crude oil;
- metal working fluids;
- molten bitumen or fumes from molten bitumen;
- shale oil; or
- soot.
Service exposure and SOP requirements
Polycyclic aromatic hydrocarbons (PAHs) are those chemical substances formed during the combustion of organic material or during high temperature processing of crude oil, coke, or other industrial carbon compounds. The SOP factor requires the exposure to be cutaneous. Cutaneous contact includes both external and internal skin (mucous membranes).
Most military personnel would not ordinarily be exposed to high levels of PAHs, however, service need only make a material contribution to the SOP quantity requirements. Information about the scope and nature of particular service occupations may be found in Physical requirements, duties, and workplace hazards of specific military occupations which also contains an embedded hotword: Military occupations with fumes and irritants component.
Last reviewed for CCPS 26 September 2007.
Investigative Documents
| Type | Title | PDF Format | Word Format |
|---|---|---|---|
| Claimant Report | Cutaneous Contact with Polycyclic Aromatic Hydrocarbons |
Preliminary questions [31328]
31329 there is some evidence that cutaneous contact with high concentrations of polycyclic aromatic hydrocarbons (PAHs) may be a factor in the development of the condition under consideration.
31333 the veteran has had cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, at some time.
31330 the veteran has established the causal connection between cutaneous contact with polycyclic aromatic hydrocarbons (PAHs) and VEA service for the clinical onset of non-melanotic malignant neoplasm of the skin.
31331 the veteran has established the causal connection between cutaneous contact with polycyclic aromatic hydrocarbons (PAHs) and operational service for the clinical onset of non-melanotic malignant neoplasm of the skin.
or
31332 the veteran has established the causal connection between cutaneous contact with polycyclic aromatic hydrocarbons (PAHs) and eligible service for the clinical onset of non-melanotic malignant neoplasm of the skin.
Clinical onset and operational service [31331]
31334 the veteran had cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, on a cumulative total of at least 1000 days, at some time.
31335 the veteran had cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, on a cumulative total of at least 1000 days, before the clinical onset of the condition under consideration.
31336 operational service made a material contribution to the veteran having cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, on a cumulative total of at least 1000 days, before the clinical onset of the condition under consideration.
Clinical onset and eligible service [31332]
38712 the veteran had cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, on a cumulative total of at least 2000 days, at some time.
38713 the veteran had cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, on a cumulative total of at least 2000 days, before the clinical onset of the condition under consideration.
31337 eligible service made a material contribution to the veteran having cutaneous contact of side and site of the body with agents containing high concentrations of polycyclic aromatic hydrocarbons (PAHs), as specified, on a cumulative total of at least 2000 days, before the clinical onset of the condition under consideration.